(Press-News.org) ATLANTA - New research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, shows that ultrasound-detected salivary gland abnormalities in primary Sjögren's become more severe over time and that the slow-to-progress disease likely starts long before it is first detected (Abstract #1371).
Sjögren's disease also known as Primary Sjögren’s syndrome, is a systemic autoimmune disorder. It is marked by inflammation of the lacrimal and salivary glands, leading to chronic dry eyes and mouth. Fatigue is common, and about one-third of patients have complications affecting the lungs, skin, kidneys, and joints. Up to 60% of patients can develop systemic symptoms.
Salivary gland ultrasonography (SGUS) is a safe and noninvasive method for diagnosing and monitoring Sjögren's. Yet it is unclear whether the abnormalities it detects become more notable over time. Valérie Devauchelle-Pensec, M.D., Ph.D., professor of rheumatology in the department of Clinical Immunology and Rheumatology at the University of Brest Occidentale and the Cavale Blanche hospital in Brest, France designed a cross-sectional international study to find out.
“I have taken care of patients with Sjögren's disease for years, and I am always surprised that when I see them at the onset of their disease, their first ultrasound of the salivary gland shows severe lesions,” Devauchelle-Pensec says. “I also have many patients with rheumatoid arthritis. In rheumatoid arthritis, joints are destroyed, but not at the onset of the disease. Sjögren's seems different. I wondered, ‘When does the disease really begin and do lesions evolve over time or not?’ Many of my colleagues who are experts in Sjögren's and ultrasound agreed to participate [in the study].”
Between May 2019 and February 2022, 247 patients from 11 international centers were consecutively enrolled in the study. Most were women, with a median age of 58. Nearly 100% of patients reported oral dryness; 75% had an abnormal salivary flow and 85% were positive for anti-SSA autoantibodies, a hallmark of Sjögren's. The median EULAR Sjögren’s disease activity score (ESSDAI) was 3, suggesting low disease activity.
Ultrasound-detected functional abnormalities of the parotid and submandibular gland were classified according to the most recent Outcome Measures in Rheumatology (OMERACT) score, a four-grade semi-quantitative scoring system. The patients were then grouped according to disease duration dating from the start of dry mouth symptoms.
Group A: less than five years (47 patients)
Group B: five to nine years (69 patients)
Group C: 10 to 20 years (78 patients)
Group D: More than 20 years (53 patients)
When the researchers looked at the most severe gland for each patient, they found a significant association between disease duration and the OMERACT score. The odds ratio for the progression during a five-year interval was 1.23.
There was no statistical difference among the groups relative to the various ultrasound parameters, with the exception of the proportion of hyperechoic bands, which are associated with damage in established Sjögren's.
“We hypothesized that hyperechoic bands represent the slow fibroadipose evolution of the disease,” Devauchelle-Pensec says. “To me, this says that Sjögren's begins long before we find it, so it is important to treat patients early.”
She adds that the study pinpoints the importance of adding ultrasound findings to the classification criteria for Sjögren's syndrome and to the need for a better understanding of when the disease begins.
###
About ACR Convergence
ACR Convergence, the annual meeting of the American College of Rheumatology, is where rheumatology meets to collaborate, celebrate, congregate, and learn. With more than 240 sessions and thousands of abstracts, it offers a superior combination of basic science, clinical science, business education and interactive discussions to improve patient care. For more information about the meeting, visit https://rheumatology.org/annual-meeting, or join the conversation on Twitter by following the official hashtag (#ACR23).
About the American College of Rheumatology
Founded in 1934, the American College of Rheumatology (ACR) is a not-for-profit, professional association committed to advancing the specialty of rheumatology that serves nearly 8,500 physicians, health professionals, and scientists worldwide. In doing so, the ACR offers education, research, advocacy and practice management support to help its members continue their innovative work and provide quality patient care. Rheumatology professionals are experts in the diagnosis, management and treatment of more than 100 different types of arthritis and rheumatic diseases. For more information, visit www.rheumatology.org
END
ATLANTA — New research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, describes a link between positive antiphospholipid antibodies and an increased risk of future cardiovascular disease in patients with systemic lupus erythematosus (SLE) (Abstract #0552).
Antiphospholipid antibodies (aPLs) are autoantibodies directed against phospholipid-binding proteins. In antiphospholipid syndrome, they are associated with heart attack, stroke, and pulmonary embolism, and with miscarriage and stillbirth during pregnancy.
People with SLE also have a greatly increased risk ...
ATLANTA - New research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, found that JAK inhibitors (JAKi) and tocilizumab elicited better response rates in VEXAS syndrome compared to other targeted therapies (Abstract #L03).
VEXAS syndrome is a rare and often fatal autoimmune condition caused by a mutation in the UBA1 gene. It is marked by widespread inflammation leading to a range of symptoms that affect the skin, lungs, blood vessels and joints. The name is an acronym for disease characteristics: vacuoles in bone marrow, E1 enzyme (the enzyme encoded by the UBA1 gene), ...
ATLANTA — New research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, describes the expansion of a novel program to train primary care physicians (PCPs) in the diagnosis and management of rheumatoid arthritis (RA) in Native American communities that have little or no access to rheumatology care (Abstract #2455).
Despite the high prevalence of RA and other rheumatologic diseases among Native Americans, many Native American communities lack adequate access to subspecialized care. As a result, responsibility for treatment has shifted to primary care providers, who often do not feel confident prescribing RA medications or ...
ATLANTA — According to new research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, continuing tumor necrosis factor inhibitors during pregnancy is not associated with worse fetal or obstetric outcomes and may reduce the risk of severe maternal infections during pregnancy (Abstract #0477).
Tumor necrosis factor (TNF) inhibitors such as adalimumab and infliximab are often prescribed for inflammatory forms of arthritis that have not improved with other treatments. Although studies suggest the drugs are safe during pregnancy, ...
ATLANTA - New research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, reports the incidence and risk factors for new-onset interstitial lung disease (ILD) in previously ILD-negative systemic sclerosis patients (Abstract #1700).
Interstitial lung disease is a common complication and cause of death in systemic sclerosis (SSc, scleroderma). Although the prevalence and risk factors for ILD are well known, less is known about the annual incidence and risk factors associated with the disease that occurs in patients who test negative on screening tests conducted at baseline. To answer these questions, Liubov Petelytska, ...
In a small study, researchers at the National Institutes of Health have found that positron emission tomography (PET) scans of the heart may identify people who will go on to develop Parkinson’s disease or Lewy body dementia among those at-risk for these diseases. The findings, published in the Journal of Clinical Investigation and led by scientists at the National Institute of Neurological Disorders and Stroke (NINDS), part of NIH, may advance efforts to detect the earliest changes that years later lead to Parkinson’s disease and Lewy body dementia.
In ...
Macarena de la Fuente, MD, chief of neuro-oncology at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, has been elected to the Society of Neuro-Oncology (SNO)’s board of directors.
She will serve as the neurology representative and becomes the first Hispanic elected to the multidisciplinary board, which strives to advance brain tumor research, education and collaboration.
De la Fuente has been an SNO member for over a decade and previously served as chair of the society’s ...
ATLANTA — New research at ACR Convergence 2023, the American College of Rheumatology’s annual meeting, demonstrates that CAR-T cell therapy could lead to sustained suppression of autoantibodies in treatment-resistant lupus while maintaining a robust response to vaccines (Abstract #0607).
Systemic lupus erythematosus (SLE, lupus) is a complex autoimmune disease marked by the production of autoantibodies to nucleic acid DNA and nuclear protein autoantigens and is associated with dysfunctional B cells. It mainly affects women and is more common and severe in people who ...
PLYMOUTH MEETING, PA [November 7, 2023] — New research in the November 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network suggests that patients who have insufficient levels of vitamin D before starting paclitaxel treatment are more likely to experience peripheral neuropathy. According to an analysis of 1,191 patients with early-stage breast cancer—using data collected in the SWOG S0221 study—20.7% of patients with vitamin D deficiency experienced at least a grade 3 level of chemotherapy-induced peripheral neuropathy (CIPN), compared to 14.2% of those with sufficient vitamin D levels. The researchers ...
The rapid adoption of zero-emission electric vehicles will move the nation close to an 80% or more drop in transportation greenhouse gas emissions by 2050 from the 2019 level according to researchers from the U.S. Department of Energy’s National Renewable Energy Laboratory (NREL).
The researchers came to that conclusion after running thousands of computer simulations on the steps needed to decarbonize passenger and freight travel, which make up the largest contributor to greenhouse gases. While they advised that “no single technology, policy, or behavioral change” is enough by itself to reach the target, eliminating tailpipe emissions would be a major factor.
“There ...
